Cobenfy for Alzheimer's Psychosis
Quick Facts
Can a schizophrenia drug treat psychosis in Alzheimer's disease?
Psychosis is a common and distressing complication of Alzheimer's disease. It can include hallucinations, such as seeing or hearing things that are not there, and delusions, such as fixed false beliefs that a spouse is an impostor or that caregivers are stealing. Research generally suggests that a substantial share of people with Alzheimer's, often estimated at roughly a third or more at some point in the illness, experience psychotic symptoms. These symptoms are linked to faster functional decline, higher caregiver burden and earlier placement in long-term care. The Alzheimer's Association estimates that more than 7 million Americans are living with Alzheimer's dementia, so even a modest share of affected patients represents a large unmet need.
Bristol Myers Squibb acquired the drug through its purchase of Karuna Therapeutics. The FDA approved the xanomeline-trospium combination, marketed as Cobenfy, in September 2024 for adults with schizophrenia. The company has since been testing it in Alzheimer's disease psychosis, and Reuters reported that preliminary data indicate symptom benefit. Preliminary results typically come from a press release or early readout, without the full statistical detail, safety breakdown and subgroup analyses that peer-reviewed publication provides. Patients and families should therefore treat the finding as encouraging rather than practice-changing.
How does a muscarinic drug differ from older antipsychotics?
Most antipsychotics, including those sometimes used off-label in dementia, work mainly by blocking dopamine D2 receptors. In older adults with dementia these drugs carry a boxed warning from the FDA for increased mortality, and they are associated with sedation, falls, movement problems and other risks. Xanomeline is an agonist at M1 and M4 muscarinic acetylcholine receptors, which are involved in cognition and in regulating dopamine signaling indirectly. Trospium is a muscarinic antagonist that does not readily cross into the brain, and it is included to blunt peripheral side effects of xanomeline such as nausea and vomiting.
The muscarinic mechanism is of particular interest in Alzheimer's disease because cholinergic neurons are among those lost in the illness, and M1 receptors have long been studied as a target for cognition. Whether stimulating these receptors can ease psychosis without worsening cognition or safety in frail older adults is exactly what late-stage trials aim to show. Reported side effects of Cobenfy in schizophrenia include nausea, vomiting, constipation, indigestion, increased heart rate and blood pressure changes. Older patients with dementia may be more vulnerable to some of these effects, so tolerability data from the Alzheimer's population will be closely examined.
What are the current treatment options and what happens next?
Clinicians typically start with non-drug strategies: looking for triggers such as infection, pain, medication side effects or sleep disruption, adjusting the environment, and supporting caregivers. When medication is considered, options are limited and carry trade-offs. Pimavanserin is approved for hallucinations and delusions associated with Parkinson's disease psychosis, but it is not approved for Alzheimer's disease psychosis. Brexpiprazole is approved in the United States for agitation associated with dementia due to Alzheimer's disease, which is a related but distinct symptom domain. This gap is one reason a drug with a new mechanism has drawn attention.
Key questions remain. These include the size of the benefit compared with placebo, how durable it is, how it affects cognition and daily function, and whether safety in older adults matches what was seen in schizophrenia. Bristol Myers Squibb has had mixed results with Cobenfy in other settings, so a benefit in one condition does not guarantee success in another. Regulators will expect complete data from adequately powered, controlled trials before approving any new indication. Families should not seek the drug off-label on the basis of preliminary data and should discuss any changes in symptoms or medications with the treating physician.
Frequently Asked Questions
No. The FDA approved Cobenfy (xanomeline-trospium) in September 2024 for adults with schizophrenia. Use in Alzheimer's disease psychosis is still under investigation, and the data reported so far are preliminary.
The FDA requires a boxed warning on antipsychotics noting an increased risk of death in older adults with dementia-related psychosis. They can also cause sedation, falls and movement-related side effects, so they are generally used cautiously and at the lowest effective dose.
Report new hallucinations or delusions to a clinician promptly, because infections, pain, medication effects or sleep problems can contribute. Non-drug measures such as calm communication, a consistent routine and good lighting are usually tried first.
References
- Reuters Health. Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows. Reuters.
- U.S. Food and Drug Administration. FDA approves first drug with new mechanism of action for treatment of schizophrenia (Cobenfy, xanomeline and trospium chloride). September 2024.
- Alzheimer's Association. Alzheimer's Disease Facts and Figures. Annual report.